Clorox（CLX）株式概要
クロロックス・カンパニーは、消費者向けおよび業務用製品を世界中で製造・販売している。 詳細
CLX Community Fair Values
Create NarrativeSee what 82 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
The Clorox Company 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$96.42 |
| 52週高値 | US$132.03 |
| 52週安値 | US$84.70 |
| ベータ | 0.55 |
| 1ヶ月の変化 | 8.23% |
| 3ヶ月変化 | -4.67% |
| 1年変化 | -22.65% |
| 3年間の変化 | -39.71% |
| 5年間の変化 | -47.99% |
| IPOからの変化 | 5,289.41% |
最新ニュース
分析記事 • Jun 16
Clorox (CLX) Stock Could Be 44% Below Fair Value Despite Recent Bounce
Clorox (CLX) stock has been drawing attention after recent performance figures showed mixed returns across different timeframes, prompting investors to reassess how the company’s current valuation lines up with its fundamentals and longer term track record. See our latest analysis for Clorox. At a share price of US$95.98, Clorox has seen its 30 day share price return rise 6.11%, while the 90 day share price return fell 13.84% and the 1 year total shareholder return declined 19.06%. This...
ナラティブの更新 • Jun 13
CLX: GOJO Integration And Healthcare Expansion Will Shape Future Portfolio Multiple
Narrative Update The analyst price target for Clorox is updated lower from $115.47 to $105.29, reflecting a series of Street revisions as analysts factor in a slightly higher discount rate, modestly adjusted revenue growth and profit margin assumptions, and a lower future P/E multiple. Analyst Commentary Recent research on Clorox reflects a broad reset in expectations, with multiple firms trimming price targets and at least one downgrade from JPMorgan.Seeking Alpha • Jun 07
The Reasons Why I Believe A Buy Rating Is Not Justified For Clorox (Rating Upgrade)
Summary Clorox managed to keep its sales flat YoY and improve its EPS slightly, despite contracting gross margins, due to elevated energy prices. Based on a dividend discount model, assuming 2% growth in perpetuity and a 7.7% required rate of return, the upside from the current price levels seems to be limited. For these reasons, I upgrade CLX to hold. Read the full article on Seeking AlphaRecent updates
分析記事 • Jun 16
Clorox (CLX) Stock Could Be 44% Below Fair Value Despite Recent Bounce
Clorox (CLX) stock has been drawing attention after recent performance figures showed mixed returns across different timeframes, prompting investors to reassess how the company’s current valuation lines up with its fundamentals and longer term track record. See our latest analysis for Clorox. At a share price of US$95.98, Clorox has seen its 30 day share price return rise 6.11%, while the 90 day share price return fell 13.84% and the 1 year total shareholder return declined 19.06%. This...ナラティブの更新 • Jun 13
CLX: GOJO Integration And Healthcare Expansion Will Shape Future Portfolio Multiple
Narrative Update The analyst price target for Clorox is updated lower from $115.47 to $105.29, reflecting a series of Street revisions as analysts factor in a slightly higher discount rate, modestly adjusted revenue growth and profit margin assumptions, and a lower future P/E multiple. Analyst Commentary Recent research on Clorox reflects a broad reset in expectations, with multiple firms trimming price targets and at least one downgrade from JPMorgan.Seeking Alpha • Jun 07
The Reasons Why I Believe A Buy Rating Is Not Justified For Clorox (Rating Upgrade)
Summary Clorox managed to keep its sales flat YoY and improve its EPS slightly, despite contracting gross margins, due to elevated energy prices. Based on a dividend discount model, assuming 2% growth in perpetuity and a 7.7% required rate of return, the upside from the current price levels seems to be limited. For these reasons, I upgrade CLX to hold. Read the full article on Seeking Alpha
ナラティブの更新 • May 30
CLX: Execution Risks And Leadership Transition Will Constrain Future Earnings Power
Clorox's analyst fair value estimate has been revised down from $94.00 to $83.00 as analysts factor in updated assumptions around discount rates, margins, and future P/E, in light of a broad wave of recent price target cuts across the Street. Analyst Commentary Recent Street research has tilted clearly cautious on Clorox, with a series of price target cuts and at least one downgrade from JPMorgan.
ナラティブの更新 • May 14
CLX: GOJO Integration And Need Based Focus Will Support Long Term Earnings
Analysts have trimmed the blended fair value estimate for Clorox to about $144 from roughly $155, as a series of firms cut price targets, citing refreshed views on growth, margins, and future P/E multiples following recent research updates. Analyst Commentary Recent research has been dominated by cuts to fair value estimates and price targets, yet there are still some constructive signals in the commentary that matter if you are focused on Clorox's long term setup rather than just near term P/E compression.ナラティブの更新 • Apr 29
CLX: GOJO Integration And Need Based Portfolio Focus Will Shape Future Multiple
Analysts have trimmed their average price target on Clorox by about $4 to reflect revised assumptions around long term revenue growth, profit margins, and future P/E multiples after a recent wave of target cuts and a downgrade from several major firms. Analyst Commentary The recent research flow on Clorox shows a clear shift toward more cautious price targets, even as some firms earlier in the year had raised their estimates following company updates and sector moves.ナラティブの更新 • Apr 15
CLX: Execution Risks On Growth Plans Will Restrain Future Earnings Power
Clorox's updated analyst price target holds at $94.00, with recent Street research showing a series of both increases and cuts as analysts factor in revised assumptions for revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street research around Clorox has shifted toward more cautious pricing, with several bearish analysts trimming their targets after reassessing revenue, margin, and P/E assumptions.ナラティブの更新 • Mar 31
CLX: Mixed Organic Trends And GOJO Integration Will Shape Balanced Future Earnings Power
Analysts have trimmed Clorox's average price target by low double digit dollar amounts to around $94. This reflects mixed revisions across firms as they weigh softer volume expectations in consumer staples against company specific initiatives such as the GOJO acquisition and an increased focus on need based product innovation.ナラティブの更新 • Mar 17
CLX: Need Based Product Innovation And GOJO Integration Will Support Earnings Outlook
Analysts have inched their average price targets on Clorox higher, with multiple firms lifting targets into the $120s as they factor in Clorox's plans for need based product innovation and expected benefits from the GOJO acquisition, even as some caution remains around mixed organic sales trends and broader staples sector headwinds. Analyst Commentary Recent research on Clorox reflects a split view, with several bullish analysts lifting price targets into the low to mid US$120s while a few high profile firms remain cautious with targets closer to US$90 to US$110.ナラティブの更新 • Mar 03
CLX: Mixed Organic Trends And GOJO Integration Will Restrain Future Earnings Power
Analysts have nudged their average price target on Clorox higher by low single digits into the $120 range, citing refreshed sector targets, mixed but stable organic sales trends, and potential B2B upside from the GOJO acquisition. Analyst Commentary Recent research on Clorox has been mixed, with several firms lifting price targets into the low to mid $120s while keeping neutral or equal weight ratings.ナラティブの更新 • Feb 17
CLX: Lingering Distribution Issues Will Cap Earnings Power And Future P/E
The analyst price target for Clorox has shifted around recent revisions, with multiple firms raising or lowering their dollar price objectives as analysts weigh updated views on long term revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research on Clorox shows a split tape, with several firms lifting their price targets while others are trimming expectations or keeping a more cautious stance.ナラティブの更新 • Feb 03
CLX: Slower Distribution Recovery Will Restrain Earnings Power And Future Multiple
Analysts have reset their fair value estimate for Clorox to $94 from $115. This reflects updated assumptions for discount rates, modest revenue growth, slightly lower profit margins, and a reduced future P/E multiple, in line with recent mixed price target moves across the Street.ナラティブの更新 • Jan 20
CLX: ERP Normalization And Volume Recovery Concerns Will Shape Multiple Re Rating
Narrative Update The updated analyst price target for Clorox has shifted slightly lower to reflect a fair value move from about $122.41 to $119.76. Analysts are factoring in recent target cuts tied to softer guidance, slower expected volume recovery, and modestly lower revenue growth, profit margin, and future P/E assumptions, partially offset by at least one small upward revision.ナラティブの更新 • Jan 05
CLX: ERP Normalization And EPS Recovery Will Support Multiple Re Rating
Analysts have trimmed their price targets on Clorox, nudging our fair value estimate down by about $2 to $122.41 as they factor in softer Q1 results, a lower-end full-year EPS guide, and slightly more conservative assumptions for growth, margins, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q1 results and the full year EPS guide, while soft, were described as not as bad as feared, which they view as supportive of current valuation levels after the recent P/E reset.ナラティブの更新 • Dec 20
CLX: Margin Recovery And ERP Progress Will Support Earnings Outlook
Clorox's analyst price target has been reduced by about $5 to reflect softer near term results and guidance, with analysts citing muted growth expectations, operating deleverage from recent disruptions, and a more cautious outlook on topline and earnings across consumer staples. Analyst Commentary Bullish analysts acknowledge that Clorox's recent results and guidance were soft, but stress that the outcome was not as negative as many investors had anticipated.ナラティブの更新 • Dec 05
CLX: ERP Normalization And Cost Controls Will Drive Earnings Recovery
Analysts have trimmed their price targets on Clorox, collectively nudging our fair value view slightly lower, toward the Street’s new mid range around $117 to $125 per share, as they factor in softer near term results, muted growth expectations, and operating deleverage tied to service disruptions and cautious FY26 and FY27 outlooks. Analyst Commentary Analysts broadly view the latest quarter as soft but not thesis breaking, with valuation resets clustering around the low to mid $120s and embedding more modest growth and profitability assumptions.ナラティブの更新 • Nov 21
CLX: Share Buybacks And Cost Controls Will Support Recovery Into Fiscal 2026
Analysts have reduced their average price target for Clorox by a modest amount, from approximately $124.76 to $124.59. This adjustment is due to softer recent results and tempered growth expectations reflected in the latest earnings guidance and sector trends.分析記事 • Nov 12
Here's Why Shareholders May Want To Be Cautious With Increasing The Clorox Company's (NYSE:CLX) CEO Pay Packet
Key Insights Clorox will host its Annual General Meeting on 19th of November Total pay for CEO Linda Rendle includes...分析記事 • Nov 10
Clorox (NYSE:CLX) Strong Profits May Be Masking Some Underlying Issues
The market shrugged off The Clorox Company's ( NYSE:CLX ) solid earnings report. We did some digging and believe...ナラティブの更新 • Nov 06
CLX: Share Buybacks And Cost Controls Will Drive Resilience Into Fiscal 2026
Clorox's fair value price target has been lowered by analysts from $129.88 to $124.76, a change that reflects softer recent financial results and modest growth expectations, which are tempered by ongoing operational challenges. Analyst Commentary Recent analyst updates for Clorox reflect a mixed outlook, with both optimistic and cautious perspectives emerging in response to the company's latest financial results and ongoing challenges.ナラティブの更新 • Oct 23
Analysts Lower Clorox Price Target Amid Service Disruptions and Muted Profit Outlook
Clorox's analyst price target was reduced from approximately $131.24 to $129.88, as analysts cite ongoing service disruptions, slowing sales growth, and a muted profit outlook as key factors for the adjustment. Analyst Commentary Recent research updates indicate that analysts remain cautious on Clorox shares, reflecting ongoing challenges and a muted growth outlook.ナラティブの更新 • Oct 09
Modern ERP And Digital Marketing Will Unlock Lasting Opportunities
Clorox’s analyst price target has been lowered by approximately $2.35 per share. Analysts cite weaker revenue growth projections and ongoing operational challenges for the company.ナラティブの更新 • Aug 27
Modern ERP And Digital Marketing Will Unlock Lasting Opportunities
Clorox’s consensus price target was revised down to $135.06 as soft consumption data, ERP-related volatility, and weak guidance have undermined near-term sales and earnings visibility. Analyst Commentary Recent soft consumption data signals weakened demand, prompting concern over short-term sales trends.分析記事 • Aug 04
Clorox (NYSE:CLX) Has Announced That It Will Be Increasing Its Dividend To $1.24
The Clorox Company ( NYSE:CLX ) will increase its dividend on the 29th of August to $1.24, which is 1.6% higher than...分析記事 • Aug 02
Earnings Beat: The Clorox Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Shareholders might have noticed that The Clorox Company ( NYSE:CLX ) filed its yearly result this time last week. The...分析記事 • Jul 16
Returns On Capital At Clorox (NYSE:CLX) Have Stalled
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Seeking Alpha • Mar 29
Clorox: Reviving From Cyberattack; Initiate With 'Buy'
Summary I am initiating a 'Buy' rating for Clorox with a fair value of $153 per share, driven by strong brand equity and IT modernization efforts. Clorox's ERP upgrade and IT investments are expected to drive future growth, despite near-term costs and recent cyberattack impacts. Clorox anticipates 3%-5% organic revenue growth and 13%-19% adjusted EPS growth in FY25, supported by new ERP system rollout and cost management. Key risks include Walmart's pricing power, potential consumer shift to private labels, and tariff exposure, though mitigated by supply chain adjustments. Read the full article on Seeking AlphaSeeking Alpha • Feb 27
Clorox: A Wonderful Business I Would Like To Own At A Lower Price
Summary Clorox is a wonderful business that sells everyday products across the world. It has many well-loved brands that customers love. The company has bounced back from the cyberattack it suffered in 2023, and has regained lost market share and improved margins. Wallstreet analysts across the board have upgraded their earnings expectations for CLX. However, there are real concerns facing it, and I do not think that investing in CLX at the current price offers me a favorable risk-reward scenario. Read the full article on Seeking AlphaSeeking Alpha • Nov 26
The Clorox Company: Hold, Trading Above Fair Value Despite Positive Signals
Summary I rate The Clorox Company a hold due to its volatile financial performance and current stock trading above fair value. Despite revenue fluctuations, Clorox has strong brand recognition and promising growth potential, with 80% of sales from top-ranked products. The company's resilience is evident through consistent dividends, high ROE, ROCE, and positive EVA, indicating shareholder value creation. Clorox's recovery is marked by significant YoY growth in revenue, net income, and operational efficiency, showcasing potential for future growth. Read the full article on Seeking Alpha株主還元
| CLX | US Household Products | US 市場 | |
|---|---|---|---|
| 7D | 1.1% | -2.2% | 1.6% |
| 1Y | -22.7% | -8.0% | 21.1% |
業界別リターン: CLX過去 1 年間で-8 % の収益を上げたUS Household Products業界を下回りました。
リターン対市場: CLXは、過去 1 年間で21.1 % のリターンを上げたUS市場を下回りました。
価格変動
| CLX volatility | |
|---|---|
| CLX Average Weekly Movement | 5.7% |
| Household Products Industry Average Movement | 3.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: CLX 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: CLXの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1913 | 7,600 | Linda Rendle | www.thecloroxcompany.com |
クロロックス・カンパニーは、消費者向け製品および業務用製品を世界中で製造・販売している。同社は4つのセグメントで事業を展開している：ヘルス＆ウェルネス、ハウスホールド、ライフスタイル、インターナショナル。ヘルス＆ウェルネス部門は、「クロロックス」、「クロロックス2」、「パインソル」、「センティバ」、「タイレックス」、「リキッド・プラムル」、「ポエット」、「フォーミュラ409」のブランドでホームケア用クリーニング・消毒製品、漂白剤、詰まり除去剤、洗濯用添加剤、「クロロックス・プロ」、「クロロックス・ヘルスケア」のブランドで業務用クリーニング・消毒製品、「ヒドゥンバレー」のブランドで業務用フードサービス製品を米国で販売している。ハウスホールド部門は、フレッシュステップとスクープアウェイブランドの猫砂製品、グラッドブランドのバッグとラップ、キングスフォードブランドのグリル製品を米国で提供している。ライフスタイル部門は、主にHidden Valleyブランドのドレッシング、ディップ、調味料、ソース、Britaブランドの浄水器製品、Burt's Beesブランドのナチュラルパーソナルケア製品を米国で提供している。国際部門は、主にクロロックス、グラッド、ポエット、ブリタ、バーツ・ビーズ、パインソル、エバークリーン、クロリンダ、チャックス、フレッシュ・ステップのブランドで、洗濯用添加剤、ホームケア製品、バッグ・ラップ、猫砂製品、浄水システム、業務用洗浄・消毒製品、ナチュラル・パーソナルケア製品、食品、グリル製品、消化器系健康製品を国際的に提供している。また、Natural Vitality、RenewLife、NeoCell、Rainbow Lightブランドでビタミン、ミネラル、サプリメント製品を提供している。同社は、量販店、食料品店、倉庫クラブ、ドルショップ、ホーム・ハードウェア・センター、ドラッグストア、ペットショップ、ミリタリーショップ、サードパーティおよび自社ECチャネル、ディストリビューター、直販部隊を通じて製品を販売している。同社は1913年に設立され、カリフォルニア州オークランドに本社を置いている。
The Clorox Company 基礎のまとめ
| CLX 基礎統計学 | |
|---|---|
| 時価総額 | US$11.54b |
| 収益（TTM） | US$756.00m |
| 売上高(TTM) | US$6.76b |
15.4x
PER（株価収益率1.7x
P/SレシオCLX は割高か？
公正価値と評価分析を参照収益と収入
| CLX 損益計算書（TTM） | |
|---|---|
| 収益 | US$6.76b |
| 売上原価 | US$3.80b |
| 売上総利益 | US$2.96b |
| その他の費用 | US$2.21b |
| 収益 | US$756.00m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 6.25 |
| グロス・マージン | 43.85% |
| 純利益率 | 11.18% |
| 有利子負債／自己資本比率 | 4,432.6% |
CLX の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
5.1%
現在の配当利回り80%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/01 12:03 |
| 終値 | 2026/07/01 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/06/30 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
The Clorox Company 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。31
| アナリスト | 機関 |
|---|---|
| John Staszak | Argus Research Company |
| Lauren Lieberman | Barclays |
| Constance Maneaty | BMO Capital Markets Equity Research |